Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
Status:
Recruiting
Trial end date:
2024-03-13
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess efficacy, safety, tolerability and
pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with
relapsed, platinum-resistant small-cell lung cancer (SCLC). This study will be conducted in
two parts: safety run-in part and main part. The safety run-in part will be conducted in
Japan.